AstraZeneca (AZN -1.6%) is partnering with Ironwood Pharmaceuticals (IRWD -1.6%) to co-develop...

|About: AstraZeneca Group plc (AZN)|By:, SA News Editor

AstraZeneca (AZN -1.6%) is partnering with Ironwood Pharmaceuticals (IRWD -1.6%) to co-develop and co-commercialize IRWD's linaclotide in China. Linaclotide is the first and only guanylate cyclase-C agonist approved by the FDA. Under the terms of the agreement, AZN will make an upfront payment of $25M to IRWD and will share in the net profits and losses. IRWD will also be eligible for $125M in additional sales-related milestone payments.